Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Classical homocystinuria due to cystathionine beta-synthase (CbS) deficiency is characterized by the multiple involvement of the eye, skeleton, central nervous system, and vascular system.
Features include always present findings: Hypermethioninemia, Ataxia, Intellectual disability, and Dysarthria and others; and very common findings: Recurrent fractures and Abnormality of amino acid metabolism. 89 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 23 | Stroke, Seizure, Ataxia |
Eyes | 9 | Lens subluxation, Retinal detachment, Visual impairment |
Bones and joints | 9 | Limitation of joint mobility, Kyphoscoliosis, Biconcave vertebral bodies |
Digestive system | 7 | Pancreatitis, Hepatic steatosis, Anorexia |
Heart and blood vessels | 5 | Stroke, Myocardial infarction, Mitral valve prolapse |
Skin | 4 | Hypopigmentation of the skin, Urticaria, Subcutaneous hemorrhage |
Muscles | 3 | Limitation of joint mobility, Brain atrophy, Damage to the optic nerve (optic atrophy) |
Growth and development | 3 | Tall stature, Failure to thrive, Disproportionate tall stature |
Head and neck | 1 | High palate |
Metabolism | 1 | Abnormality of amino acid metabolism |
Lungs and breathing | 1 | Pulmonary embolism |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |
Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency (HCU-CBS deficiency) is characterized by involvement of the eye, skeletal system, vascular system, and central nervous system (CNS). One to all four of the systems can be involved. Expressivity is variable for all clinical manifestations. It is not unusual for a previously asymptomatic individual to present in adulthood or earlier with only a thromboembolic event that is often cerebrovascular . Individuals with HCU-CBS deficiency can be vitamin B6 responsive, vitamin B6 nonresponsive, or partial responders to vitamin B6.
Source: GeneReviews — "Homocystinuria due to Cystathionine Beta-Synthase Deficiency"
CBS encodes cystathionine beta-synthase (551 aa). Hydro-lyase catalyzing the first step of the transsulfuration pathway, where the hydroxyl group of L-serine is displaced by L-homocysteine in a beta-replacement reaction to form L-cystathionine, the precursor of L-cysteine. Highest expression in Liver (6.6 TPM) and Brain Cerebellum (5.6 TPM).
Classic homocystinuria is caused by mutations in the CBS gene on chromosome 21.
The CBS protein participates in SeHCys and Ser are dehydrated into SeCysta by CBS, PXLP-CBS tetramers condenses HCYS and L-Ser to form L-Cystathionine, and Defective ABCD4:LMBRD1 does not transport Cbl from lysosomal lumen to cytosol pathways.
CBS is classified as a druggable target (Enzyme category) with score 10.4.
Guidelines for the diagnosis of homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency (HCU-CBS deficiency) have been published .
HCU-CBS deficiency should be suspected in an infant with an or a and family history. Note: (1) Individuals with untreated HCU-CBS deficiency usually develop manifestations in the first or second decade of life. (2) A symptomatic individual can have untreated HCU-CBS deficiency due to NBS not performed, false negative NBS result, or caregivers not adherent to recommended treatment after a positive NBS result.
NBS for HCU-CBS deficiency is primarily based on use of dried blood spots collected between 24 and 72 hours after birth to quantify methionine concentration, typically by tandem mass spect...
Source: GeneReviews — "Homocystinuria due to Cystathionine Beta-Synthase Deficiency"
The clinical condition that most closely mimics homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency (HCU-CBS deficiency) is Marfan syndrome (an autosomal dominant disorder caused by pathogenic variants in FBN1), which shares the features of long, thin body habitus, arachnodactyly, and predisposition for ectopia lentis and myopia. Although ectopia lentis can also occur early in isolated sulfite oxidase deficiency (an autosomal recessive disorder caused by pathogenic variants in SUOX), this condition is clinically distinct from homocystinuria. Individuals with sulfite oxidase deficiency and Marfan syndrome have normal concentrations of plasma homocysteine and methionine.
Source: GeneReviews — "Homocystinuria due to Cystathionine Beta-Synthase Deficiency"
Genetic testing for CBS is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for classic homocystinuria has been reported in the published literature.
No approved treatments are currently available for classic homocystinuria. The disease remains an area of unmet medical need.
Gene therapy approaches for classic homocystinuria have been reported in the published literature.
Clinical practice guidelines for management of homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency (HCU-CBS deficiency) have been published .
To establish the extent of disease and needs in an individual diagnosed with HCU-CBS deficiency, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 4.
Homocystinuria due to Cystathionine Beta-Synthase Deficiency: Recommended Evaluations After Establishing a Diagnosis
System/Concern | Evaluation | Comment
| Consultation w/metabolic physician/ biochemical geneticist specialist metabolic dietitian1 | • Transfer to specialist center w/experience in mgmt of inherited metabolic diseases (strongly recommended).
Consider short hospitalization at center of expertise for inherited metabolic conditions to provide caregivers w/detailed education (re diet mgmt risk of vascular event) initiate treatment following pyridoxine challenge.
Pyridoxine (vitamin B6) challenge prior to initiation of treatment (See .)
Eyes | Ophthalmology eval | Evaluate for myopia ectopia lentis.
| Clinical assessment for scoliosis, arachnodactyly, pes cavus, pectus deformity, genu valgum | Radiographs for scoliosis as needed
| Consultation w/neurologist | In those w/possible seizures extrapyramidal signs such as dystonia
Eval per vascular specialist | In those presenting w/vascular event
| By gene...
Source: GeneReviews — "Homocystinuria due to Cystathionine Beta-Synthase Deficiency"
5 trials found
The evaluations summarized in are recommended to monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations.
Table 10.
Homocystinuria due to Cystathionine Beta-Synthase Deficiency: Recommended Surveillance
Manifestation | Evaluation | Frequency/Comment
Metabolic/
| • Eval w/metabolic specialist metabolic dietitian
Plasma total homocysteine, plasma amino acids (incl methionine), folate, vitamin B12
| Frequency per metabolic specialist based on severity of disorder, vitamin B6 responsiveness, adherence to treatment, age, history of venous thrombosis1
CBC iron studies (ferritin, iron, total iron-binding capacity)
Vitamin mineral testing (25-hydroxyvitamin D level, zinc)
Prealbumin
Additional labs as clinically indicated may include methylmalonic acid, serum calcium, phosphate, other vitamins trace minerals, essential fatty acids.2
| In those on methionine-restricted diet per metabolic specialist2
| Ophthalmology exam to evaluate for myopia ectopia lentis | At least annually1
| Assess for long bone overgrowth deformity, genu valgum, pes cavus, pectus deformity, kyphosis/scoliosis, frequency of fractures. | At each visit
Radiographs for scoliosis | As needed
DXA scan | Every 3-5 yrs from adolescence; more frequent in those w/frequent fractures /or low vitamin D concentration
| • Lipid profile to assess cardiovascular risk factors
Source: GeneReviews — "Homocystinuria due to Cystathionine Beta-Synthase Deficiency"
Phenotype severity distribution: 10 always present features, 2 very common features, 19 common features.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
5 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3, 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06247085](https://clinicaltrials.gov/study/NCT06247085) | A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment | PHASE3 | Travere Therapeutics, Inc. | RECRUITING |
[NCT06431893](https://clinicaltrials.gov/study/NCT06431893) | A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) | PHASE3 | Travere Therapeutics, Inc. | ENROLLING_BY_INVITATION |
[NCT06556615](https://clinicaltrials.gov/study/NCT06556615) | Health Related Quality of Life (HrQoL) in Classical Homocystinuria (CBS Deficiency) | — | University Children's Hospital, Zurich | RECRUITING |
[NCT02998710](https://clinicaltrials.gov/study/NCT02998710) | Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) | — | Travere Therapeutics, Inc. | UNKNOWN |
[NCT03406611](https://clinicaltrials.gov/study/NCT03406611) | Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) | PHASE1 | Travere Therapeutics, Inc. | RECRUITING |
27 publications have been identified in PubMed for classic homocystinuria. Research spans Basic Science / Preclinical (26%), Case Report / Case Series (22%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 7 | 26% |
Patient case studies | 6 | 22% |
Disease patterns and progression | 5 | 19% |
Research summaries | 4 | 15% |
Clinical study results | 3 | 11% |
Testing and diagnosis research | 1 |
Kahraman S (2026). [PMID: 41174154](https://pubmed.ncbi.nlm.nih.gov/41174154/). *Pediatric research*. [Clinical Trial Publication]
Aljaberi R (2026). [PMID: 40771008](https://pubmed.ncbi.nlm.nih.gov/40771008/). *American journal of medical genetics. Part A*. [Review / Meta-Analysis]
Joschko CP (2026). [PMID: 41977510](https://pubmed.ncbi.nlm.nih.gov/41977510/). *Int J Mol Sci*. [Gene Therapy / Novel Therapeutics]
Cruikshank A (2026). [PMID: 41947028](https://pubmed.ncbi.nlm.nih.gov/41947028/). *CPT Pharmacometrics Syst Pharmacol*. [Basic Science / Preclinical]
Kodali AT (2026). [PMID: 42111688](https://pubmed.ncbi.nlm.nih.gov/42111688/). *Arch Clin Cases*. [Case Report / Case Series]
Zhang Z (2026). [PMID: 41943097](https://pubmed.ncbi.nlm.nih.gov/41943097/). *BMC Med Genomics*. [Case Report / Case Series]
Thibodeau J (2026). [PMID: 41692349](https://pubmed.ncbi.nlm.nih.gov/41692349/). *Biochemical pharmacology*. [Basic Science / Preclinical]
Philipp TM (2026). [PMID: 41478486](https://pubmed.ncbi.nlm.nih.gov/41478486/). *International journal of biological macromolecules*. [Basic Science / Preclinical]
Kahraman S (2025). [PMID: 40987823](https://pubmed.ncbi.nlm.nih.gov/40987823/). *Pediatric research*. [Clinical Trial Publication]
Alzwaihri AS (2025). [PMID: 40337434](https://pubmed.ncbi.nlm.nih.gov/40337434/). *Annals of medicine and surgery (2012)*. [Epidemiology / Natural History]
Data assembled from 9 of 12 sources · Last updated Sep 19, 2026, 7:51 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
New treatment approaches | 1 | 4% |